World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 26 June 2023
Main ID:  ISRCTN43310942
Date of registration: 22/05/2015
Prospective Registration: No
Primary sponsor: Geneva University Hospitals
Public title: Two self-sampling methods (Vaginal dry swabs vs. FTA-elute cartridge) for HPV detection.
Scientific title: Randomized comparison of two self-sampling methods (Vaginal dry swabs vs. FTA-elute cartridge) for HPV detection.
Date of first enrolment: 01/03/2014
Target sample size: 130
Recruitment status: Completed
URL:  https://www.isrctn.com/ISRCTN43310942
Study type:  Interventional
Study design:  Women will be invited to perform two self-sampling (FTA and v-DRY) in our colposcopy clinic in Geneva. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic test (Real-time PCR). (Prevention)  
Phase:  Not Applicable
Countries of recruitment
Switzerland
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name: Rosa    Catarino
Address:  Boulevard de la Cluse 30 1205 Genève Switzerland
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. At least 30 years old
2. Attending colposcopy clinic
3. Understands study procedures and accepts voluntarily to participate by signing the informed consent form (ICF)

Exclusion criteria: 1. Pregnancy
2. Previous Hysterectomy
3. Virgin
4. Not able to comply with protocol study


Age minimum:
Age maximum:
Gender: Female
Health Condition(s) or Problem(s) studied
Cervical pre-cancer and cancer.
Cancer
Intervention(s)
Women were invited to perform two self-sampling (FTA and v-DRY). Randomization of the sequence of the two self-HPV tests was done to avoid potential bias that may advantage the “first” test.
The research nurse would then give oral instructions to the patients. For specimen collection, participants were instructed to wash their hands before the procedure. Each participant received a package containing specimen collection kit. The brush used for self-collection using the FTA cartridge was the Rovers Viva-brush (Rovers Medical Devices B.V., Oss, The Netherlands), whereas the swab used for the self-collection in the v-DRY method was the flocked mid-turbinate swab (Copan FLOQSwabs™; Copan, Italy). Recommendations were to hold the brush/swab by the end of the handle, to insert the brush/swab into the vagina, avoiding contact with the external genitalia, until they meet resistance (at least 6 cm). Once they met resistance, they should gently turn the brush/swab three to five times. Subsequently the brush should be applied to the FTA cartridge by pressing it onto the middle of sample area indicated and then rotate de brush 3-5 times across that area. On the other hand, the swab was just inserted inside its plastic sleeve (v-DRY).

During the colposcopy consultation, the physician collected also a sample using specimen transport medium (Copan ESwab, Brescia, Italy) for HPV testing.

HPV analysis was performed using the Anyplex II HPV28 (H28) Detection test (Seegene, Seoul, South Korea).
Primary Outcome(s)
Agreement between collection methods in terms of HPV positivity, measured using kappa statistic and corresponding standard deviation.
Secondary Outcome(s)
1. Sensitivity and specificity to detect high-risk HPV using the result from the physician’s collected samples as gold standard was reported, as well as, sensitivity and specificity of the three sampling methods for abnormal Pap smear. Because of the small number of high-grade squamous intraepithelial lesion (HSIL) or carcinomas in our population, we assessed sensitivity and specificity for low-grade squamous intraepithelial lesion or greater lesions (LSIL+). The two-tailed McNemar’s test was used for mutual comparison of sensitivity and specificity.
2. Positive and negative predictive values to detect high-risk HPV using the physician’s collected samples as gold standard
3. Positive and negative predictive values of the three sampling methods to detect high-risk HPV for abnormal Pap smear results
4. Agreement between collection methods in terms of HPV positivity, according to cytological results
Agreement between collection methods according to cytological results was measured using kappa statistic and corresponding standard deviation
5. Proportion of positive agreement (PPA) between paired FTA and Vaginal dry swabs (v-DRY) samples. The proportion of positive agreement (PPA) between paired FTA and v-DRY samples was calculated by using the following formula: 2a/(f1+g1), where a=the number of samples that were positive for HPV in both dry samples, f1=the number of samples that were positive for FTA and g1=the number of samples that were positive for v-DRY
6. Proportion of positive agreement (PPA) between paired self collection methods (combined results of FTA and v-DRY) and physician’s collected sample. The proportion of positive agreement (PPA) between paired self collection methods and physician’s collected samples was calculated by using the following formula: 2a/(f1+g1), where a=the number of samples that were positive for HPV in both samples, f1=the number of samples that were positive for the self-collection methods and g1=the number of samples that were positive for the physician’s collected sample
7. Women’s preference regarding the collection methods. Women completed a self-administered questionnaire

Data will be analyzed with a statistical analysis software package (StataCorp.2013., Stata Statistical Software: Release 13. College Station, TX, USA).
Secondary ID(s)
Nil known
Source(s) of Monetary Support
Research Projects for Development (Projets Recherche & Développement) (PRD) - HUG
Secondary Sponsor(s)
Ethics review
Status:
Approval date:
Contact:
Old ethics approval format; Cantonal Human Research Ethics Commission of Geneva, 17/.02/2014, ref: CCER, CER: 14-011
Results
Results available: Yes
Date Posted:
Date Completed: 01/03/2015
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history